<code id='F4C76F0B94'></code><style id='F4C76F0B94'></style>
      • <acronym id='F4C76F0B94'></acronym>
      <center id='F4C76F0B94'><center id='F4C76F0B94'><tfoot id='F4C76F0B94'></tfoot></center><abbr id='F4C76F0B94'><dir id='F4C76F0B94'><tfoot id='F4C76F0B94'></tfoot><noframes id='F4C76F0B94'>
      • <optgroup id='F4C76F0B94'><strike id='F4C76F0B94'><sup id='F4C76F0B94'></sup></strike><code id='F4C76F0B94'></code></optgroup>
        5. <b id='F4C76F0B94'><label id='F4C76F0B94'><select id='F4C76F0B94'><dt id='F4C76F0B94'><span id='F4C76F0B94'></span></dt></select></label></b><u id='F4C76F0B94'></u>
          <i id='F4C76F0B94'><strike id='F4C76F0B94'><tt id='F4C76F0B94'><pre id='F4C76F0B94'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          entertainment 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          fashion  
          
                                   
                 
                                      author：leisure time   
                                        
                                      
                                      -
 
browse：87684
                                  
                                    
          
                                    
            
          
 
          Adobe
          KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.
          Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.
          advertisement
          In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
           
 
 
          

                              
          
                                 Previous article：

                                
                                          The cancer drug shortage isn’t new — and neither are the solutions
                                
                            
          Next article：  
                                      
                                          The 10 drugs up first for Medicare price negotiation
                                                                    
          

      
           
      
           
        
           
                                               
        
           knowledge 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          knowledge
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          hotspot
           
                                      
            
           
          
           
                                                          
             
          knowledge
           
                             
            
           
            
           

                                                         
             
          Wikipedia
           
               
              
            
           
            
           
                                                         
             
          hotspot
           
                             
      
           
 
     
           
     
           
      
          
              RubyWallauforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP477name